tiprankstipranks
Trending News
More News >
Ansell (AU:ANN)
ASX:ANN

Ansell (ANN) AI Stock Analysis

Compare
32 Followers

Top Page

AU

Ansell

(Sydney:ANN)

Rating:73Outperform
Price Target:
AU$35.00
▲(15.25%Upside)
Ansell's overall stock score of 73 is primarily driven by strong financial performance in cash flow management and a positive earnings call showcasing growth and strategic initiatives. While technical indicators suggest neutral momentum, valuation concerns due to a high P/E ratio are offset by an attractive dividend yield. The absence of significant corporate events ensures the focus remains on these key areas.

Ansell (ANN) vs. iShares MSCI Australia ETF (EWA)

Ansell Business Overview & Revenue Model

Company DescriptionAnsell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by hospitals, surgical centers, dental practices, veterinary clinics, first responders, laboratories, and life sciences and pharmaceutical companies. The Industrial segment manufactures and markets hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia. P. D. Holdings Pty. Ltd. operates as a current subsidiary of Ansell Limited.
How the Company Makes MoneyAnsell makes money through the sale of its personal protective equipment across its core business segments: Healthcare and Industrial. In the Healthcare segment, the company generates revenue by providing a variety of medical-grade gloves and protective clothing used in surgical, examination, and infection control applications. For the Industrial segment, Ansell offers high-performance gloves, clothing, and other PPE designed for industries such as automotive, chemical, food processing, and construction, where worker safety is paramount. The company also benefits from strategic partnerships and collaborations with distributors and retailers worldwide, enhancing its market reach and product availability. Additionally, Ansell invests in research and development to innovate and improve its product offerings, which supports its competitive edge and drives sales growth.

Ansell Earnings Call Summary

Earnings Call Date:Feb 09, 2025
(Q2-2025)
|
% Change Since: 13.40%|
Next Earnings Date:Aug 26, 2025
Earnings Call Sentiment Positive
The earnings call presented a strong performance with significant growth in both the Healthcare and Industrial segments, successful integration of the KBU acquisition, and an increase in EPS guidance. Despite facing challenges such as freight costs, raw material inflation, and tariff uncertainties, the company demonstrated resilience and strategic planning. The overall sentiment is positive as the highlights significantly outweigh the lowlights.
Q2-2025 Updates
Positive Updates
Double-Digit Growth in Top and Bottom Line
Reported double-digit growth in both top and bottom line, with a 21% increase in EBIT on an organic basis and exceeding all FY '25 first half year performance objectives.
Strong Organic Sales Growth in Healthcare and Industrial
Healthcare achieved a 16% organic growth, while Industrial saw an 8% increase. This growth was driven by new products and overcoming destocking effects.
Successful KBU Integration
The KBU business exceeded expectations with a 7% sales growth and strong margins. The integration is on track to complete ahead of schedule.
Increased EPS Guidance
Confidence in the second half performance led to an increase in the overall EPS guidance range for the year.
Improved Balance Sheet Flexibility
Net debt-to-EBITDA leverage of 1.6x, which is well below expectations, providing increased balance sheet flexibility.
Record GPADE Margins
GPADE margins improved by 140 basis points due to higher margins from the KBU acquisition and operating leverage.
Strong Cash Flow and Inventory Management
Operating cash flow of just under $54 million with a healthy cash conversion of 104%. Improved inventory turns and tight management of receivables and payables.
Negative Updates
Impact of Freight Costs
Freight costs were a headwind to margins due to the use of more expensive air freight to build up channel safety stocks.
Inflationary Pressures on Raw Materials
Continued inflation in key raw material items, such as nitrile and natural rubber latex, and in conversion costs due to minimum wage increases.
Potential Revenue Leakage in KleenGuard
Some anticipated revenue leakage in the KleenGuard safety portfolio due to transitional integration phases.
Tariff Uncertainty
Uncertainty regarding tariffs, particularly concerning products sourced from China, which could impact future profitability.
Company Guidance
During the Ansell Limited FY '25 Half Year Results Call, CEO Neil Salmon reported a robust financial performance with double-digit growth in both top and bottom lines, attributed to exceeding all first half year performance objectives. The company achieved 16% organic growth in Healthcare and 8% in Industrial, boosted by the acquisition of KBU and a productivity program. Ansell's EBIT grew by 21% on an organic basis, and the net debt-to-EBITDA leverage was at 1.6x, indicating strong financial health. Salmon announced an increased EPS guidance range for the year and highlighted strategic investments, including the APIP program on track for a $50 million pretax savings by fiscal year '26. New product success in the Industrial segment and a recovery from destocking in Healthcare, along with a strong balance sheet, were key contributors to Ansell's results.

Ansell Financial Statement Overview

Summary
Ansell demonstrates strong cash flow management and a stable balance sheet, though profitability metrics such as declining revenue and net profit margins have weakened in recent years. Strong operating and free cash flow provide financial flexibility despite these challenges.
Income Statement
65
Positive
Ansell's revenue has shown a declining trend over the past three years, with a noticeable decrease from 2022 to 2024. Gross profit margin is strong at approximately 38.6%, but net profit margin has decreased significantly, indicating declining profitability. EBIT and EBITDA margins are healthy but have also declined compared to past years, reflecting reduced operational efficiency.
Balance Sheet
75
Positive
The balance sheet reveals a stable equity position with a strong equity ratio of around 58.4%. The debt-to-equity ratio is moderate at 0.45, suggesting manageable leverage. Return on equity has deteriorated, reflecting challenges in generating returns for shareholders.
Cash Flow
80
Positive
Ansell's operating cash flow has improved significantly, indicating strong cash generation. Free cash flow has shown robust growth, enhancing financial flexibility. The company maintains a solid operating cash flow to net income ratio, highlighting effective cash conversion.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
1.85B1.62B1.63B1.85B2.04B1.61B
Gross Profit
725.00M624.80M604.22M625.19M807.21M632.70M
EBIT
217.20M56.70M210.50M233.62M265.80M181.50M
EBITDA
291.80M202.30M275.20M291.90M401.60M261.30M
Net Income Common Stockholders
112.10M76.50M148.30M158.70M246.70M158.70M
Balance SheetCash, Cash Equivalents and Short-Term Investments
268.90M912.30M159.03M206.18M240.21M411.51M
Total Assets
3.27B3.24B2.52B2.51B2.74B2.45B
Total Debt
825.70M857.20M493.15M485.74M515.53M581.19M
Net Debt
556.80M-55.10M334.12M279.57M275.31M169.68M
Total Liabilities
1.35B1.33B913.07M949.48M1.17B1.05B
Stockholders Equity
1.91B1.89B1.60B1.54B1.55B1.39B
Cash FlowFree Cash Flow
219.90M208.60M95.37M127.71M72.17M218.30M
Operating Cash Flow
272.90M272.30M161.72M191.71M155.40M280.93M
Investing Cash Flow
-688.70M-63.40M-74.54M-67.51M-85.25M-72.97M
Financing Cash Flow
518.10M540.80M-130.82M-148.76M-250.72M-189.56M

Ansell Technical Analysis

Technical Analysis Sentiment
Negative
Last Price30.37
Price Trends
50DMA
30.80
Negative
100DMA
32.77
Negative
200DMA
32.37
Negative
Market Momentum
MACD
-0.22
Positive
RSI
35.02
Neutral
STOCH
2.96
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ANN, the sentiment is Negative. The current price of 30.37 is below the 20-day moving average (MA) of 31.35, below the 50-day MA of 30.80, and below the 200-day MA of 32.37, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 35.02 is Neutral, neither overbought nor oversold. The STOCH value of 2.96 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:ANN.

Ansell Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
AURMD
79
Outperform
AU$56.90B28.2025.23%1.31%10.54%38.69%
AUANN
73
Outperform
$4.44B24.686.45%2.29%16.30%1.08%
54
Neutral
$5.34B3.36-45.10%3.39%16.81%-0.03%
$5.45B1,147.730.52%2.00%
AUREG
58
Neutral
AU$2.29B151.70-276.16%2.10%25.38%
AUCU6
53
Neutral
AU$716.61M-53.99%-40.19%
AUTRJ
45
Neutral
AU$106.66M-24.66%0.70%-1600.91%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:ANN
Ansell
30.54
4.82
18.73%
RMSYF
Ramsay Health Care
25.25
-6.46
-20.37%
AU:CU6
Clarity Pharmaceuticals Ltd.
2.24
-3.00
-57.25%
AU:TRJ
Trajan Group Holdings Ltd
0.73
-0.21
-22.34%
AU:REG
Regis Healthcare Ltd.
7.62
3.43
81.86%
AU:RMD
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
38.59
6.86
21.62%

Ansell Corporate Events

Ansell Announces Board Changes Amidst Succession Plan
May 20, 2025

Ansell Limited announced changes to its Board of Directors as part of its ongoing succession and renewal plan. Non-Executive Director Morten Falkenberg will retire at the end of May 2025, and Randy Stone will join as an independent Non-Executive Director in August 2025. Stone brings extensive international experience and expertise in industries closely aligned with Ansell’s focus, which is expected to enhance the Board’s capabilities and support the company’s strategic goals.

The most recent analyst rating on (AU:ANN) stock is a Hold with a A$40.00 price target. To see the full list of analyst forecasts on Ansell stock, see the AU:ANN Stock Forecast page.

Ansell Limited Announces Change in Substantial Shareholding
Apr 14, 2025

Ansell Limited has reported a change in the substantial holding of its shares, indicating a shift in the voting power and relevant interests of its stakeholders. The announcement highlights the involvement of State Street Corporation and its subsidiaries, which have adjusted their holdings and voting power in Ansell. This change may impact the company’s governance and decision-making processes, reflecting a strategic realignment of interests among its major shareholders.

Allan Gray Australia Increases Stake in Ansell Limited
Apr 7, 2025

Allan Gray Australia Pty Ltd, an investment manager, has increased its voting power in Ansell Limited from 15.63% to 16.90% as of April 3, 2025. This change in substantial holding reflects a strategic move by Allan Gray Australia to strengthen its influence within Ansell, potentially impacting the company’s governance and decision-making processes.

Ansell Navigates New US Tariffs with Strategic Pricing Adjustments
Apr 3, 2025

Ansell Limited has announced that new tariffs on imports into the US will affect approximately 43% of its revenue, as the majority of its products sold in the US are sourced from Asian countries now subject to these tariffs. To mitigate the impact, Ansell plans to adjust pricing and has communicated with customers regarding these changes. The company remains flexible in its manufacturing capabilities with 14 owned plants across nine countries, allowing it to adapt to shifts in manufacturing attractiveness. Despite the tariffs, Ansell maintains its guidance range for FY25 Adjusted EPS, indicating confidence in its strategic approach.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.